Bioactive Products
| A unique collection of 674 anticancer natural compounds for high throughput screening (HTS) and New anticancer drug research | ||
| Catalog No: | B91 | Anticancer Compound Library Screening Details |
| Size: | 1mg/well * 674 Compounds 2mg/well * 674 Compounds | |
| Cat. No. | Information |
| CFN92011 | 9-Methoxycanthin-6-one 9-Methoxycanthin-6-one has anti-tumour activity, exhibits cytotoxic activity towards KB, LU-1, LNCaP, HL-60 cancer cells and other human cancer cell lines with IC50 values around 1-4 μg/mL. |
| CFN92016 | 8-Prenylnaringenin 8-Prenylnaringenin is a phytoestrogen with high estrogenic activity, it shows more potent effects on promoting osteoblastic bone formation and inhibiting osteoclastic bone resorption by ERα instead of ERβ than the two classic phytoestrogens: genistein and daidzein. 8-Prenylnaringenin at all assayed doses (0.001-20 µM) presumably improves mitochondrial function, whereas a high dose of XN (5 µM) worsens the functionality of this organelle. |
| CFN92017 | 6-Prenylnaringenin 6-Prenylnaringenin is an isomer of the potent phytoestrogen, 8-prenylnaringenin. It exhibits both mixed and non-competitive inhibitory characteristics against tyrosinase, tyrosinase is the rate-limiting enzyme for the production of melanin and other pigments via the oxidation of l-tyrosine. 6-Prenylnaringenin has anti-cancer potential , dose-dependent reduction of cellular proliferation of human PC-3 prostate cancer and UO.31 renal carcinoma cells upon treatment. 6-Prenylnaringenin can inhibit 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced inflammation (1μg/ear) in mice, it also exhibits inhibitory effects on skin-tumor promotion in anin vivo two-stagemouse-skin carcinogenesis test based on 7,12-dimethylbenz[a]- anthracene (DMBA) as initiator and with TPA as promoter. |
| CFN92022 | Przewaquinone A Przewaquinone A has antitumor activity. |
| CFN92028 | Furanodienone Furanodienone inhibits EGFR/HER2 signaling pathway in BT474 and SKBR3 cells, the effect is specifically dependent on the expression of HER2 but not EGFR; it also has effects on MCF-7 cells are mediated, at least in part, by inhibiting ERα signaling. |
